Therapeutic potential and clinical translation of nanodrugs: A path forward- case studies from bench to bedside
- 7 July 2025
- journal article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 112
Abstract
No abstract availableThis publication has 240 references indexed in Scilit:
- A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st CenturyAdvanced Materials, 2024
- Externally Controlled Trials: Are We There Yet?Clinical Pharmacology & Therapeutics, 2020
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular CarcinomaJAMA Oncology, 2019
- Thermo‐triggered Release of CRISPR‐Cas9 System by Lipid‐Encapsulated Gold Nanoparticles for Tumor TherapyAngewandte Chemie International Edition, 2017
- Considerations for the clinical use of contrast agents for cellular MRI in regenerative medicineContrast Media & Molecular Imaging, 2013
- Vincristine: Can its therapeutic index be enhanced?Pediatric Blood & Cancer, 2009
- Engineered nanoparticles as precise drug delivery systemsJournal of Cellular Biochemistry, 2006
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomitingCancer, 2003
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 2001
- Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialCancer, 1988